Octreotide for acromegaly treatment: A reappraisal

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 17, 2013, Pages 2433-2447

  Giustina, Andrea ^a   Karamouzis, Ioannis ^a   Patelli, Ilaria ^a   Mazziotti, Gherardo ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Acromegaly treatment; Biochemical control; Octreotide; Shrinkage; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE;

ACROMEGALY; ADENOMA; ADVERSE OUTCOME; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILIARY TRACT DISEASE; CELL CYCLE ARREST; CHOLELITHIASIS; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEPATOBILIARY DISEASE; HUMAN; HYPERINSULINEMIA; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PROLACTINOMA; QT PROLONGATION; RADIOIMMUNOASSAY; SIDE EFFECT; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; NEOPLASMS; OCTREOTIDE;

EID: 84887889967     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.847090     Document Type: Article

References (151)

1. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355(24):2558-73
2. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2(1):29-41
3. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91(12):4769-75
4. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41(1):95-102
5. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89(2):667-74
6. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94(5):1509-17
7. Giustina A, Mazziotti G, Fontanella M. Commentary: Post-surgical monitoring of acromegaly. Neurosurgery 2013;73(4):E746-8
8. Kaltsas GA, Isidori AM, Florakis D, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001;86(4):1645-52
9. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure. Eur J Endocrinol 2005;152(3):379-87
10. Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: Long-Term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000;85(10):3779-85
11. Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89(4):1613-17
12. Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: Update after an additional 10 years. J Clin Endocrinol Metab 2005;90(2):800-4
13. Minniti G, Scaringi C, Enrici RM. Radiation techniques for acromegaly. Radiat Oncol 2011;6:167
14. Schalin-Jäntti C, Valanne L, Tenhunen M, et al. Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: A 5.25-year follow-up study. Clin Endocrinol 2010;73(1):72-7
15. Giustina A, Zaltieri G, Negrini F, Wehrenberg WB. The pharmacological aspects of the treatment of acromegaly. Pharmacol Res 1996;34(5-6):247-68
16. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83(9):3034-40
17. Amato G, Mazziotti G, Rotondi M, et al. Long-Term effects of lanreotide SR and octreotiDe LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002;56(1):65-71
18. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87(10):4554-63
19. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Efficacy of Sandostatin LAR (long-Acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004;60(3):375-81
20. Grottoli S, Celleno R, Gasco V, et al. Efficacy and safety of 48 weeks of treatment with octreotiDe LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study. J Endocrinol Invest 2005;28(11):978-83
21. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: Results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006;64(3):342-51
22. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotiDe LAR: A long-Term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91(4):1397-403
23. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotiDe LAR (long-Acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66(6):859-68
24. Maiza JC, Vezzosi D, Matta M, et al. Long-Term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67(2):282-9
25. Giustina A, Bronstein MD, Casanueva FF, et al. Current management practices for acromegaly: An international survey. Pituitary 2011;14(2):125-33
26. Plewe G, Beyer J, Krause U, et al. Long-Acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984;2(8406):782-4
27. Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-Term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985;313(25):1576-80
28. Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 2012;published online 11 Oct 2012; doi:10.1007/s11102-012- 0432-6
29. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179(4068):77-9
30. Mandarino L, Stenner D, Blanchard W, et al. Selective effects of somatostatin-14,-25 and-28 on in vitro insulin and glucagonsecretion. Nature 1981;291(5810):76-7
31. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16(4):427-42
32. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20(3):157-98
33. Guillemin R. Peptides in the brain: The new endocrinology of the neuron. Science 1978;202(4366):390-402
34. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19(6):717-97
35. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 2013;9(5):265-76
36. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994;78(2):398-403
37. Lamberts SW, Van Der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334(4):246-54
38. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31(11):1133-40
39. Yang LP, Keating GM. OctreotiDe Long-Acting release (LAR): A review of its use in the management of acromegaly. Drugs 2010;70(13):1745-69
40. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993;25(5):375-91
41. Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships. Metabolism 1996;45(8 Suppl 1):27-30
42. Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol 2000;53(6):719-24
43. Fløgstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: A dose-range study. J Clin Endocrinol Metab 1995;80(12):3601-7
44. Astruc B, Marbach P, Bouterfa H, et al. Long-Acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45(7):836-44
45. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 2000;85(2):526-9
46. Holdaway IM, Bolland MJ, Gamble GD. A meta-Analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159(2):89-95
47. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83(11):3808-16
48. Bianchi A, Giustina A, Cimino V, et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 2009;94(6):2015-22
49. Bianchi A, Mazziotti G, Tilaro L, et al. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 2009;12(3):196-9
50. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-8
51. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009;94(2):523-7
52. Ch'ng LJ, Sandler LM, Kraenzlin ME, et al. Long term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J (Clin Res Ed) 1985;290(6464):284-5
53. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 1990;71(2):391-7
54. Vance ML, Harris AG. Long-Term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151(8):1573-8
55. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117(9):711-18
56. Christensen SE, Weeke J, Orskov H, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf) 1987;27(3):297-306
57. Tauber JP, Babin T, Tauber MT, et al. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 1989;68(5):917-24
58. Stewart PM, Kane KF, Stewart SE, et al. Depot long-Acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80(11):3267-72
59. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1(2):105-14
60. Freda PU, Katznelson L, Van Der Lely AJ, et al. Long-Acting somatostatin analog therapy of acromegaly: A meta-Analysis. J Clin Endocrinol Metab 2005;90(8):4465-73
61. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93(8):2957-68
62. Davies PH, Stewart SE, Lancranjan L, et al. Long-Term therapy with long-Acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48(3):311-16
63. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-Acting repeatable in 110 acromegalic patients: Predictive value of short-Term results? J Clin Endocrinol Metab 2003;88(7):3090-8
64. Cozzi R, Dallabonzana D, Attanasio R, et al. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999;141(3):267-71
65. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotiDe LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999;51(3):275-80
66. van Thiel SW, Romijn JA, Biermasz NR, et al. OctreotiDe Long-Acting repeatable and lanreotide autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150(4):489-95
67. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotiDe LAR. Eur J Endocrinol 2004;151(3):317-24
68. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide autogel in patients with acromegaly previously treated with octreotiDe LAR. Eur J Endocrinol 2004;150(4):473-80
69. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotiDe Long acting release (LAR): An open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007;67(4):512-19
70. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151(4):439-46
71. Bex M, Abs R, T'Sjoen G, et al. AcroBel-The Belgian registry on acromegaly: A survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007;157(4):399-409
72. Trainer PJ. ACROSTUDY: The first 5 years. Eur J Endocrinol 2009;161(Suppl 1):S19-24
73. Giustina A. Keep an eye on nonfunctioning pituitary adenomas. Clin Endocrinol 2012;77(5):656-7
74. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152(1):61-6
75. Jallad RS, Musolino NR, Kodaira S, et al. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 2007;67(2):310-15
76. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82(10):3308-14
77. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-Term postoperative rates: A prospective, randomized trial. J Clin Endocrinol Metab 2008;93(8):2984-90
78. Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 2013;98(3):1040-50
79. Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 2008;158(1):19-25
80. Ramírez C, Vargas G, Gonźalez B, et al. Discontinuation of octreotiDe LAR after long term, successful treatment of patients with acromegaly: Is it worth tryinǧ Eur J Endocrinol 2012;166(1):21-6
81. Shin MS, Yu JH, Choi JH, et al. Long-Term changes in serum IGF-1 levels after successful surgical treatment of growth hormone secreting pituitary adenoma. Neurosurgery 2013;published online 30 May 2013; doi:10.1227/01.neu. 0000431480. 87160.84
82. Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine. J Clin Endocrinol Metab 1987;64(3):447-53
83. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008;37(1):67-99
84. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65(2):265-73
85. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90(3):1856-63
86. Losa M, Ciccarelli E, Mortini P, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86(11):5194-200
87. Giustina A, Mazziotti G, Torri V, et al. Meta-Analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012;7(5):e36411
88. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999;28(1):45-79
89. Abe T, Lüdecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145(2):137-45
90. Colao A, Ferone D, Marzullo P, et al. Long-Term effects of depot long-Acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779-86
91. Jenkins PJ, Emery M, Howling SJ, et al. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotiDe LAR. Horm Res 2004;62(5):227-32
92. Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: No improvement of final growth hormone (GH) concentration and pituitary function. A long-Term case-control study. Acta Neurochir (Wien) 2005;147(5):485-93
93. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90(7):4405-10
94. Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: Remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011;96(9):2732-40
95. Colao A, Pivonello R, Auriemma RS, et al. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-Acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 2008;93(9):3436-42
96. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-Acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007;92(5):1592-9
97. Gola M, Bonadonna S, Mazziotti G, et al. Resistance to somatostatin analogs in acromegaly: An evolving concept? J Endocrinol Invest 2006;29(1):86-93
98. Kiriş A, Erem C, Turan OE, et al. Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine 2012;published online 20 December 2012; doi:10.1007/s12020-012-9859-9
99. Grasso L, Colao A. Left ventricular synchronicity in acromegaly. Endocrine 2013;In press
100. Giustina A, Gola M, Colao A, et al. The management of the patient with acromegaly and headache: A still open clinical challenge. J Endocrinol Invest 2008;31(10):919-24
101. Claessen KM, Ramautar SR, Pereira AM, et al. Progression of acromegalic arthropathy despite long-Term biochemical control: A prospective, radiological study. Eur J Endocrinol 2012;167(2):235-44
102. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: Prevalence and determinants. Clin Endocrinol (Oxf) 2005;63(4):470-6
103. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013;16(3):294-302
104. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-52
105. Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: A metaanalysis. J Clin Endocrinol Metab 2007;92(5):1743-7
106. De Marinis L, Bianchi A, Mazziotti G, et al. The long-Term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 2008;11(1):13-20
107. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-Aged patients after 12 months of treatment with the depot long-Acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003;58(2):169-76
108. Weiss V, Sonka K, Pretl M, et al. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 2000;23(8):515-19
109. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991;115(7):527-32
110. De Menis E, Giustina A, Colao A, et al. Assessment of the awareness and management of sleep apnea syndrome in acromegaly. J Endocrinol Invest 2011;34(1):60-4
111. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: Correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001;55(4):477-83
112. Chanson P, Timsit J, Benoit O, et al. Rapid improvement in sleep apnoea of acromegaly after short-Term treatment with somatostatin analogue SMS 201-995. Lancet 1986;1(8492):1270-1
113. Davi' MV, Dalle Carbonare L, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 2008;159(5):533-40
114. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29(5):535-59
115. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women. J Bone Miner Res 2005;20(10):1837-44
116. Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008;93(12):4649-55
117. Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-Term controlled acromegaly. Eur J Endocrinol 2011;164(4):475-83
118. Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: A 3-year prospective study. J Clin Endocrinol Metab 2013;published online Jun 2013; doi:10.1210/jc.2013-1460
119. Battista C, Chiodini I, Muscarella S, et al. Spinal volumetric trabecular bone mass in acromegalic patients: A longitudinal study. Clin Endocrinol 2009;70(3):378-82
120. Mazziotti G, Gola M, Bianchi A, et al. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 2011;40(1):102-8
121. Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary 2002;5(1):17-19
122. Sardella C, Lombardi M, Rossi G, et al. Short-And long-Term changes of quality of life in patients with acromegaly: Results from a prospective study. J Endocrinol Invest 2010;33(1):20-5
123. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-Term cure of growth hormone excess. J Clin Endocrinol Metab 2004;89(11):5369-76
124. Colao A, Pivonello R, Galderisi M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008;93(7):2639-46
125. Arosio M, Macchelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients-A multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133(4):430-9
126. Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 2003;26(6):533-8
127. Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: A metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94(5):1500-8
128. Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotiDe LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 2011;164(3):341-7
129. Redfern JS, Fortuner WJ II. Octreotide-Associated biliary tract dysfunction and gallstone formation: Pathophysiology and management. Am J Gastroenterol 1995;90(7):1042-52
130. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients. J Endocrinol Invest 2008;31(8):704-10
131. Paisley AN, Roberts ME, Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf) 2007;66(5):723-6
132. Bubiński R, Kuś W, Goch J. Effect of somatostatin on the conduction system of the heart. Kardiol Pol 1993(4):258-62
133. Drugs to be avoided by congenital long QT patients. Center for Education and Research on Therapeutics. The University of Arizona Health Sciences Center. 2002. Available from: Www.QTdrugs.org [Last accessed 2 January 2013]
134. Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) 2006;65(5):626-30
135. Ben-Shlomo A, Melmed S. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003;88(3):963-8
136. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008;37(1):101-22
137. Fiebrich HB, Van Den Berg G, Kema IP, et al. Deficiencies in fat-soluble vitamins in long-Term users of somatostatin analogue. Aliment Pharmacol Ther 2010;32(11-12):1398-404
138. Katznelson L, Atkinson JL, Cook DM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update: Executive summary. Endocr Pract 2011;17(4):636-46
139. Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157(5):579-87
140. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: A randomised controlled trial. Eur J Endocrinol 2009;161(2):331-8
141. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24(1):28-47
142. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: A meta-Analysis. J Clin Endocrinol Metab 2011;96(5):1327-35
143. Sandostatin LAR core data sheet. Novartis AG; 2013
144. Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;97(7):2362-9
145. Bianchi A, Valentini F, Iuorio R, et al. Long-Term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-Acting somatostatin analogs: A retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 2013;32:40
146. Colao A, Arnaldi G, Beck-Peccoz P, et al. Pegvisomant in acromegaly: Why, when, how. J Endocrinol Invest 2007;30(8):693-9
147. Tulipano G, Bonfanti C, Milani G, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001;73(5):344-51
148. Wilson C. Pharmacotherapy: Pasireotide shows promise for the treatment of acromegaly. Nat Rev Endocrinol 2010;6(8):417
149. Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: A randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine 2012;42(2):366-74
150. Petersenn S, Farrall AJ, Block C, et al. Long-Term efficacy and safety of subcutaneous pasireotide in acromegaly: Results from an open-ended, multicenter, phase II extension study. Pituitary 2013;published online 26 Mar 2013; doi:10.1007/s11102-013-0478-0
151. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: Basic and clinical aspects. Trends Endocrinol Metab 2011;22(12):499-506.